# A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct07311694/  
OnCo record `nct07311694` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HRS-4357 in prostate cancer, now recruiting.

## Summary

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07311694, led by Jiangsu HengRui Medicine, and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer. Planned enrolment is 370 participants (estimated). The study started in 2026-02-02 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07311694
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label, Multicenter Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Jiangsu HengRui Medicine
- Enrolled: 370

## Sources

- ClinicalTrials.gov NCT07311694: https://clinicaltrials.gov/study/NCT07311694

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [HRS-4357](https://onco.cc/drugs/hrs-4357/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07311694.json